Table 1 Comparisons of baseline demographics and characteristics in patients with severe COVID-19
From: Effects of early corticosteroid use in patients with severe coronavirus disease 2019
Characteristics | Early use group (n = 12) | Late use group (n = 10) |
|---|---|---|
Age (years) mean ± SD | 65.6 ± 5.6 | 74.6 ± 4.6 |
Sex, No. (%) | ||
 Male | 6/12 (50%) | 6/10 (60%) |
Coexisting disease, No. (%) | ||
 Hypertension | 7/12 (58.3%) | 4/10 (30%) |
 Diabetes | 3/12 (25%) | 3/10 (30%) |
 Malignant neoplasm | 2/12 (16.7%) | 1/10 (10%) |
Symptoms | ||
 Fever | 9/12 (75%) | 7/10 (70%) |
 Cough | 6/12 (50%) | 3/10 (30%) |
 Sputum | 5/12 (41.7%) | 4/10 (40%) |
 Dyspnea | 5/12 (41.7%) | 4/10 (40%) |
 Myalgia | 5/12 (41.7%) | 2/10 (20%) |
 Fatigue | 5/12 (41.7%) | 1/10 (10%) |
 Poor oral intake | 4/12 (33.3%) | 1/10 (10%) |
Initial score on ordinal scale | ||
 No limit of activity | 0 | 0 |
 Limit of activity but no O2 | 4/12 (33.3%) | 4/10 (40%) |
 O2 with nasal prong | 5/12 (41.7%) | 2/10 (20%) |
 O2 with facial mask | 0 | 0 |
 High flow nasal cannula | 3/12 (25%) | 3/10 (30%) |
 Non-invasive ventilation | 0 | 0 |
 Invasive ventilation | 0 | 0 |
 Baseline score missing | 0 | 1/10 (10%) |
Initial PaO2/FiO2 ratio | 124.89 ± 42.60 | 133.35 ± 49.40 |